Lantern Pharma Unveils AI-Powered Tool to advance ADC Development for Cancer

Lantern Pharma has introduced a novel artificial intelligence (AI)-driven tool aimed at enhancing the accuracy, affordability, and speed of antibody-drug conjugates (ADCs) development for cancer. The AI company listed on Nasdaq is enhancing the use of its unique RADR AI platform, which utilizes AI and machine learning (ML) to improve ADC development.

As stated by Lantern Pharma, RADR AI employs more than 100 billion oncology data points and over 200 sophisticated ML algorithms to tackle significant obstacles in the development of oncology drugs. Lantern Pharma announced that it is moving forward with multiple ADC candidates in preclinical development.

The firm is additionally working with the MAGICBULLET::Reloaded Initiative at the University of Bielefeld located in Germany. At the outset, this collaboration will concentrate on the synthesis and assessment of ADCs connected to cryptophycins, a powerful antitumor compound.

Lantern Pharma's primary development efforts encompass a Phase 2 clinical program and several Phase 1 trials. Panna Sharma, the CEO and president of Lantern Pharma, stated: “This innovation shows how AI can revolutionize the typically expensive and lengthy ADC development process.”

"Through the concurrent assessment of various data types and the integration of mutation profiles with target expression, our team successfully discovered the best therapeutic combinations that could be more effective and safer for particular patient groups."

In a study that underwent peer review, Lantern Pharma demonstrated the potential of its AI-powered RADR AI platform.